Navigation Links
Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
Date:10/4/2007

h has advanced clinical programs that include new oral treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well defined, growing library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please go to http://www.immtechpharma.com.

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for PCP, which are not historical facts are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2007 and in its other SEC filings and include: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidate, including PCP; (vii) the success of Immtech's clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to have a third party manufacture its drug candidate at a reasonable cost; (x) Immtech's ability to pro
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and ... AZN ) today announced that they have entered into ... preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, ... VEGF Receptor 2 antiangiogenic cancer medicine. The planned study ... with advanced solid tumors. The Phase I ...
(Date:5/29/2015)... , May 29, 2015 Educating ... of the Association for the Advancement of Wound ... With support from AAWC,s corporate partners, the ... Portal on the AAWC website at ... wound care pathway with links to various CME/CEU ...
(Date:5/28/2015)... HOUSTON , May 28, 2015 /PRNewswire/ - ESSA ... financial results for the second quarter and three and six ... expressed in Canadian dollars and in accordance with International Financial ... ESSA recorded a net loss of $5.9 million ($0.35 ... 2015 (Q2-2015), compared to a net loss of $0.4 million ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14The Association for the Advancement of Wound Care Educates the Public 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... Presented at the 132nd Annual Meeting of the American Neurological ... Association in ... presented results from two,Phase III pivotal trials and one open-label ... restless legs,syndrome (RLS). These rotigotine data showed significant drops in ...
... Boehringer Ingelheim,Pharmaceuticals, Inc. today announced that ... full (traditional) approval of Aptivus(R),(tipranavir) capsules. The ... 2005; accelerated approval is a regulatory process ... or life-threatening illnesses. The full,approval of APTIVUS ...
Cached Medicine Technology:Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 2Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 3Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 4Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 5Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 2Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 3Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 4Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 5Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 6Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 7Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 8
(Date:5/29/2015)... May 29, 2015 This is ... state of the Naproxen industry.The report provides a ... applications and industry chain structure. The Naproxen ... markets including development trends, competitive landscape analysis, and ... discussed as well as manufacturing processes and cost ...
(Date:5/29/2015)... 2015 The FSH Society ... science of the little-known and incurable disease, facioscapulohumeral ... the second FSHD Trial Preparedness Workshop. The Workshop, ... University of Rochester Medical Center in Rochester, New ... around the world, including representatives from industry, the ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 ... H1 2015” provides comprehensive information on the ... strengthens R&D pipelines by identifying new targets ... products. Complete report on H1 2015 pipeline ... data tables and 13 figures, spread across ...
(Date:5/29/2015)... For the third year, Nike Ultimate Camps will ... ultimate community an opportunity to experience ultimate training techniques in ... of the USAU Nike Ultimate Camp is to provide a ... character, and make lifelong friends. , The USAU Nike Ultimate ... skill and ability levels, ages 10-18. Camp will run from ...
(Date:5/29/2015)... 2015 A multi-center study led ... a urine test can determine if a patient ... Dr. James McKiernan presented these findings at the ... , Dr. McKiernan is the urologist-in-chief at ... chair of the Department of Urology at Columbia ...
Breaking Medicine News(10 mins):Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2Health News:International Conference Brings Together Key Stakeholders to Advance Clinical Trial Readiness for FSHD 2Health News:International Conference Brings Together Key Stakeholders to Advance Clinical Trial Readiness for FSHD 3Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:US Sports Camps, Nike Sports Camps, and USA Ultimate Host Third Summer of Ultimate Camp in Denver 2Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 2Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 3
... YORK, Aug. 27 Dr. Steven Victor, CEO of Las ... announce the airing of their infomercial promoting laser assisted liposuction. This is ... , , The laser makes the procedure of ... can virtually go back to work the next day with very little bruising ...
... , , , PHOENIX, Aug. 27 ... family members to serve as caregivers for older adults. Caregiving can be ... amazing gift to allow a loved one to "age in place" rather ... Medicare Advantage Plan, offers these seven secrets to success for caregivers of ...
... , , , ... has been named this year,s honorary chair for the Los Angeles Jewish ... one of the largest and most popular walks to take place each ... Sunday, December 6, in Reseda. , , ...
... Lifetime of Achievement Traces Arc of American Dream , , ... in New York City ... venture capitalist and philanthropist, will be Grand Marshal of the 2009 Columbus Day Parade in ... of Home Depot and chairman of the NYU Langone Medical Center, will lead contingents of ...
... SHANGHAI, Aug. 27 /PRNewswire-Asia/ -- Linkwell Corporation (OTC Bulletin,Board: ... in China, announced that its 90% held,subsidiary, Shanghai Likang ... of Likang -- The Establishment of One Hundred Model,Hospitals, ... to September,2010. , The COO ...
... , Former President Will Address Issues ... Aug. 27 Chicago House & Social Service Agency, the first organization ... HIV and AIDS, will host their first ever Speaker Series Luncheon on ... , The luncheon will feature a speech from President ...
Cached Medicine News:Health News:Seven Secrets to Successful Caregiving of Older Adults 2Health News:Award-Winning Actress and Director Anjelica Huston Selected as Honorary Chair for L.A. Jewish Home's 'Walk of Ages X' 2Health News:Award-Winning Actress and Director Anjelica Huston Selected as Honorary Chair for L.A. Jewish Home's 'Walk of Ages X' 3Health News:Kenneth G. Langone, Home Depot Co-Founder, Chairman of the NYU Langone Medical Center, to Lead 65th Annual Columbus Day Parade as Grand Marshal 2Health News:Kenneth G. Langone, Home Depot Co-Founder, Chairman of the NYU Langone Medical Center, to Lead 65th Annual Columbus Day Parade as Grand Marshal 3Health News:Kenneth G. Langone, Home Depot Co-Founder, Chairman of the NYU Langone Medical Center, to Lead 65th Annual Columbus Day Parade as Grand Marshal 4Health News:Linkwell Corporation Announces Launch of the 'Establishment of 100 Model Hospitals' Across China 2Health News:Linkwell Corporation Announces Launch of the 'Establishment of 100 Model Hospitals' Across China 3Health News:President Bill Clinton to Speak at Inaugural Chicago House Speaker Series Luncheon 2
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... provide protection to the exposed airway of the ... making it ideal for active young children as ... heat and moisture recovery, it ensures patient comfort ... filters have ISO standard tapered ends to assure ...
... Seven digital models cover the range from 2ul ... fluently. Volume lock design prevents inadvertent volume ... horizontal grip. Whole pipette is autoclavable at ... is all polypropylene. Suitable for one-handed operation. ...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: